Document:

EX-10.36

 Exhibit 10.36 

EMPLOYMENT AGREEMENT 

This EMPLOYMENT AGREEMENT (this “Agreement”), dated April 8, 2016 and effective on the date of consummation of
the initial closing of the private placement offering of the Company’s common stock (the “Effective Date”), is by and between ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., a Delaware corporation (the “Company”) and
Steven J. Rychnovsky (the “Executive”). 
 W I T N E S S E T H: 

WHEREAS, the Company desires to employ the Executive as its Vice President of Operations and Product Development and the Executive
desires to accept such employment, on the terms and conditions set forth in this Agreement; and 
 WHEREAS, the Company and the
Executive have mutually agreed that, as of the Effective Date, this Agreement shall govern the terms of employment between the Executive and the Company. 

NOW, THEREFORE, in consideration of the promises and the mutual covenants and agreements contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows: 

ARTICLE 1 
 EMPLOYMENT; TERM OF
AGREEMENT 
 Section 1.1. Employment and Acceptance. During the Term (as defined in Section 1.2), the Company
shall employ the Executive, and the Executive shall accept such employment and serve the Company, in each case, subject to the terms and conditions of this Agreement. 

Section 1.2. Term. The employment relationship hereunder shall be for the period commencing on the Effective Date and, subject to
earlier termination as provided in ARTICLE 4, ending on the second (2nd ) anniversary of the Effective Date (the “Term”). In the event that the Executive’s employment
with the Company terminates, the Company’s obligation to continue to pay, after the Termination Date (as defined in Section 4.2(b)), Base Salary (as defined in Section 3.1(a)), Annual Bonus (as defined in
Section 3.1(b)) and other unaccrued benefits shall terminate, except as may be provided for in ARTICLE 4. 
 ARTICLE 2
 
 TITLE; DUTIES AND OBLIGATIONS; LOCATION 

Section 2.1. Title. The Company shall employ the Executive to render exclusive and full-time services to the Company. The
Executive shall serve in the capacity of Vice President of Operations and Product Development. 

 Section 2.2. Duties. The Executive shall report to the Company’s Chief
Executive Officer (the “CEO”) and be subject to the lawful direction of the CEO. The Executive agrees to perform to the best of his ability, experience and talent those acts and duties, consistent with the position of Vice President
of Operations and Product Development as the CEO shall from time to time direct. During the Term, the Executive also shall serve in such other executive-level positions or capacities as may, from time to time, be reasonably requested by the CEO,
including, without limitation (subject to election, appointment, re-election or re-appointment, as applicable) as (a) a member of the Board of Directors of the
Company (the “Board”) and/or as a member of the board of directors or similar governing body of any of the Company’s subsidiaries or other Affiliates (as defined below), (b) an officer of any of the Company’s subsidiaries
or other Affiliates, and/or (c) a member of any committee of the Company and/or any of its subsidiaries or other Affiliates, in each case, for no additional compensation. As used in this Agreement, “Affiliate” of any individual
or entity means any other individual or entity that directly or individual controls, is controlled by, or is under common control with, the individual or entity. 

Section 2.3. Compliance with Policies, etc. During the Term, the Executive shall be bound by, and comply fully with, all of the
Company’s policies and procedures for employees and officers in place from time to time, including, but not limited to, all terms and conditions set forth in the Company’s employee handbook, compliance manual, codes of conduct and any
other memoranda and communications applicable to the Executive pertaining to the policies, procedures, rules and regulations, as currently in effect and as may be amended from time to time. These policies and procedures include, among other things
and without limitation, the Executive’s obligations to comply with the Company’s rules regarding confidential and proprietary information and trade secrets. 

Section 2.4. Time Commitment. During the Term, the Executive shall use his best efforts to promote the interests of the Company
(including its subsidiaries and other Affiliates) and shall devote all of his business time, ability and attention to the performance of his duties for the Company and shall not, directly or indirectly, render any services to any other person or
organization, whether for compensation or otherwise, except with the Board’s prior written consent, provided that the foregoing shall not prevent the Executive from (i) participating in charitable, civic, educational, professional,
community or industry affairs, or (ii) managing the Executive’s passive personal investments, so long as, in each case, such activities individually or in the aggregate do not materially interfere or conflict with the Executive’s
duties hereunder or create a potential business or fiduciary conflict (in each case, as determined by the Board). 
 Section 2.5.
Location. The Executive understands that his primary place of employment shall be the Executive’s home office in the Washington, D.C. area; provided, however, that the Executive shall also be required to perform services
from time to time at the Company’s principal office in Princeton, New Jersey as reasonably requested by the Company’s Chief Executive Officer, and to travel to other such places as necessary to perform his duties hereunder. 

ARTICLE 3 
 COMPENSATION AND
BENEFITS; EXPENSES 
 Section 3.1. Compensation and Benefits. For all services rendered by the Executive in any capacity
during the Term (including, without limitation, serving as an officer, director or member of any committee of the Company or any of its subsidiaries or other Affiliates), the Executive shall be compensated as follows (subject, in each case, to the
provisions of ARTICLE 4 below): 

  
 -2- 

 (a) Base Salary. During the Term, the Company shall pay the Executive a base salary
(the “Base Salary”) at the annualized rate of $249,000, which shall be subject to customary withholdings and authorized deductions and be payable in equal installments in accordance with the Company’s customary payroll
practices in place from time to time. The Executive’s Base salary shall be subject to periodic adjustments as the Board and/or the Compensation Committee of the Board (the “Compensation Committee”) shall in its/their discretion
deem appropriate; provided, however, that (1) following the current private placement offering (the initial closing of which is occurring as of the Effective Date), upon the closing of an additional underwritten round of financing
(including equity, debt or convertible debt financing, and whether in one transaction or a series of related transactions) with gross proceeds of at least $20 million (exclusive of proceeds from investor warrants), that results in the listing
of the Company’s shares on a major exchange such as Nasdaq or the New York Stock Exchange if the shares are not already so listed, the annualized rate of Base Salary shall increase by $25,000 and (2) upon the approval of a Company NDA, the
annualized rate of Base Salary shall increase by $75,000. As used in this Agreement, the term “Base Salary” shall refer to Base Salary as may be adjusted from time to time.     

(b) Annual Bonus. For each calendar year ending during the Term (beginning with the calendar year ending December 31, 2016), the
Executive shall be eligible to receive an annual bonus (the “Annual Bonus”) with a target amount equal to thirty percent (30%) of the Base Salary earned by the Executive for such calendar year (the “Target Annual
Bonus”). The actual amount of each Annual Bonus will be based upon the level of achievement of the Company’s corporate objectives and the Executive’s individual objectives, in each case, as established by the Board or the
Compensation Committee (taking into account the input of the CEO with respect to the establishment of the Executive’s individual objectives) for the calendar year with respect to which such Annual Bonus relates. The determination of the level
of achievement of the corporate objectives and the Executive’s individual performance objectives for a year shall be made by the Board or the Compensation Committee (taking into account the input of the CEO with respect to the establishment of
the Executive’s individual objectives), in its reasonable discretion. Each Annual Bonus for a calendar year, to the extent earned, will be paid in a lump sum in the following calendar year, within the first 75 days of such following year. The
Annual Bonus shall not be deemed earned until the date that it is paid. Accordingly, in order for the Executive to receive an Annual Bonus, the Executive must be actively employed by the Company at the time of such payment.    

 (c) Equity Compensation. Subject to the terms of the Company’s 2016 Equity Incentive Plan (the “Plan”) and
approval of the Board or Compensation Committee, upon or immediately following the final closing of the private placement offering of the Company’s common stock, the Executive will be granted options to purchase up to the number of shares equal
to two and one-half percent (2.5%) of the Fully-Diluted (as defined in the Plan) shares of the Company’s common stock, on the terms and conditions determined by the Board or the Compensation Committee,
with an exercise price of $5.00 per share (provided that the Board or the Compensation Committee determines that such exercise price represents no less than fair market value per share on the date of grant in accordance with the Plan), with a
vesting schedule 

  
 -3- 

 
and other terms and conditions to be determined by the Compensation Committee. During the Term, subject to the terms and conditions established within the Plan or any successor equity
compensation plan as may be in place from time to time and separate award agreements, the Executive also shall be eligible to receive from time to time stock options, stock unit awards, performance shares, performance units, incentive bonus awards,
other cash-based awards and/or other stock-based awards (as permitted by the Plan), in amounts, if any, to be approved by the Board or the Compensation Committee in its discretion. Notwithstanding anything in the Plan to the contrary, in the event
that Executive is terminated without Cause (as defined in Section 4.1(b)) or resigns with Good Reason (as defined in Section 4.1(c)) within twenty-four (24) months following a Change in Control (as defined in
Section 5.19), in lieu of the application of Section 4.1(d)(ii), Executive shall receive accelerated vesting upon the Termination Date as if the Executive had provided service to the Company for an additional nine
(9) months, and all of Executive’s outstanding vested stock options shall remain exercisable for a period of nine (9) months, measured from the Termination Date (but in no event later than the expiration date of their term);
provided, however, that in the event stock options under the Plan are cancelled or otherwise terminated pursuant to the Plan in connection with such Change in Control, the Executive’s stock options may be cancelled or otherwise
terminated, as applicable, on terms no less favorable than those provided to other similarly situated option holders. This Section 3.1(d) shall be deemed an amendment to each award agreement entered into by the Executive evidencing a grant of
stock options, whether entered into prior to the Effective Date or during the Term (but, in no event shall this Section 3.1(d) be deemed an amendment to any award agreement entered into after expiration of the Term). 

(d) Benefit Plans. The Executive shall be entitled to participate in all employee benefit plans and programs (excluding severance plans,
if any) generally made available by the Company to senior executives of the Company, to the extent permissible under the general terms and provisions of such plans or programs and in accordance with the provisions thereof. The Company may amend,
modify or rescind any employee benefit plan or program and/or change employee contribution amounts to benefit costs without notice in its discretion. 

(e) Paid Vacation. The Executive shall be entitled to paid vacation days in accordance with the Company’s vacation policies in
effect from time to time for its executive team; provided, however, that the Executive shall be entitled to no less than fifteen (15) paid vacation days per calendar year during the Term. 

Section 3.2. Expense Reimbursement. The Company shall reimburse the Executive during the Term, in accordance with the
Company’s expense reimbursement policies in place from time to time, for all reasonable out-of-pocket business expenses incurred by the Executive in the performance
of his duties hereunder. In order to receive such reimbursement, the Executive shall furnish to the Company documentary evidence of each such expense in the form required to comply with the Company’s policies in place from time to time. 

  
 -4- 

 ARTICLE 4 

TERMINATION OF EMPLOYMENT 

Section 4.1. Termination Without Cause or Resignation for Good Reason. 

(a) The Company may terminate the Executive’s employment hereunder at any time without Cause (other than by reason of death or Disability)
upon sixty (60) days prior written notice to the Executive. Executive may terminate his employment hereunder for Good Reason upon written notice to the Company in accordance with the provisions set forth in Section 4.1(c). 

(b) As used in this Agreement, “Cause” means: (i) a material act, or act of fraud, committed by the Executive that is
intended to result in the Executive’s personal enrichment to the detriment or at the expense of the Company or any of its Affiliates; (ii) the Executive is convicted of a felony; (iii) gross negligence or willful misconduct by the
Executive, or failure by the Executive to perform the duties or obligations reasonably assigned to the Executive by the CEO (or the Board) from time to time, which is not cured upon ten (10) days prior written notice (unless such negligence,
misconduct or failure is not susceptible to cure, as determined in the reasonable discretion of the Board); or (iv) the Executive violates the Covenants Agreement (as defined in Section 5.1 below). 

(c) As used in this Agreement, “Good Reason” means the occurrence of any of the following: (1) a material breach by the
Company of the terms of this Agreement; (2) a material reduction in the Executive’s Base Salary (other than pursuant to a reduction uniformly applicable to all senior executives of the Company); or (3) a material diminution in the
Executive’s authority, duties or responsibilities; provided, however, that the Executive must notify the Company within ninety (90) days of the occurrence of any of the foregoing conditions that he considers it to be a
“Good Reason” condition and provide the Company with at least thirty (30) days in which to cure the condition. If the Executive fails to provide this notice and cure period prior to his resignation, or resigns more than six
(6) months after the initial existence of the condition, his resignation will not be deemed to be for “Good Reason.” It is an express condition of this Agreement that an acquiring entity in a Change in Control assume this Agreement;
if this Agreement is not so assumed, it shall constitute a material breach of the terms of the Agreement. 
 (d) If the Executive’s
employment is terminated pursuant to Section 4.1(a), the Executive shall, in full discharge of all of the Company’s obligations to the Executive, be entitled to receive, and the Company’s sole obligation to the Executive under
this Agreement or otherwise shall be to pay or provide to the Executive, the following: 
 (i) the Accrued Obligations
(as defined in Section 4.2(b)); 
 (ii) for each outstanding stock option held by the Executive under the Plan for which
vesting is time-based, accelerated vesting upon the Termination Date as if the Executive had provided service to the Company for an additional six (6) months, and all of the Executive’s outstanding vested stock options shall remain
exercisable for a period of six (6) months, measured from the Termination Date (but in no event later than the expiration date of their term); and 

(iii)subject to Section 4.4 and Section 4.5: 

  
 -5- 

 (A) payments equal to the sum of six (6) months’ of the
Executive’s Base Salary at the rate in effect immediately prior to the Termination Date (provided that if such salary has been reduced, the pre-reduction Base Salary) (less applicable withholdings and
authorized deductions) (the “Severance Payments”) to be paid (subject to Section 5.16) in equal installments bimonthly in accordance with the Company’s regular payroll practices, commencing on the next regular
payroll date that occurs on or after the sixtieth (60th) day following the Termination Date; provided, however, that the Severance Payments will cease in the event that Executive secures substantially gainful employment from a new
employer prior to the expiration of the time such Severance Payments are to be paid (and Executive agrees to immediately inform the Company if he becomes employed by a new employer); and 

(B) if the Executive then participates in the Company’s medical and/or dental plans and the Executive timely elects to
continue and maintain group health plan coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), then the Company shall reimburse the Executive for the healthcare continuation payments
under COBRA actually made by the Executive for the coverage period beginning on the day following the Termination Date and ending on the earlier of: (A) the six (6) month anniversary of the Termination Date; and (B) the date
the Executive becomes eligible to obtain alternate healthcare coverage from a new employer (the “COBRA Assistance”). The Executive agrees to immediately inform the Company if he becomes eligible to obtain alternate healthcare
coverage from a new employer. The Executive also agrees to remit to the Company on a monthly basis and within thirty (30) days of the date of payment, paid invoices for each such monthly COBRA premium for which he seeks reimbursement pursuant
to this Section 4.1(d)(iii)(B) and such reimbursement (to the extent required pursuant to this Section 4.1(d)(iii)(B)) shall be made to the Executive within thirty (30) days following the Executive’s delivery to the
Company of each such invoice. Notwithstanding anything set forth in this Section 4.1(d)(iii)(B), if and to the extent that the Company may not provide such COBRA Assistance without incurring tax penalties or violating any requirement of
the law, the Company shall use its commercially reasonable best efforts to provide substantially similar assistance in an alternative manner provided that the cost of doing so does not exceed the cost that the Company would have incurred had the
COBRA Assistance been provided in the manner described above or cause a violation of Section 409A (as defined in Section 5.16). 

Section 4.2. Termination for Cause; Voluntary Termination; Expiration of Term. 

(a) The Company may terminate the Executive’s employment hereunder at any time for Cause upon written notice to the Executive. The
Executive may voluntarily terminate his employment hereunder at any time without Good Reason upon sixty (60) days prior written notice to the Company; provided, however, the Company reserves the right, upon written notice to the
Executive, to accept the Executive’s notice of resignation and to accelerate such notice and make the Executive’s resignation effective immediately, or on such other date prior to Executive’s intended last day of work as the Company
deems appropriate. It is understood and agreed that the Company’s election to accelerate Executive’s notice of resignation shall not be deemed a termination by the Company without Cause for purposes of Section 4.1 of this
Agreement or otherwise or constitute Good Reason (as defined in Section 4.1) for purposes of Section 4.1 of this Agreement or otherwise. The Executive’s employment shall automatically terminate upon the expiration of the
Term in accordance with Section 1.2. 

  
 -6- 

 (b) If the Executive’s employment is terminated pursuant to Section 4.2(a),
the Executive shall, in full discharge of all of the Company’s obligations to the Executive, be entitled to receive, and the Company’s sole obligation under this Agreement or otherwise shall be to pay or provide to the Executive, the
following (collectively, the “Accrued Obligations”): 
 (i) the Executive’s earned, but unpaid, Base
Salary through the final date of the Executive’s employment by the Company (the “Termination Date”), payable in accordance with the Company’s standard payroll practices; 

(ii) the Executive’s accrued, but unused, vacation (in accordance with the Company’s policies); 

(iii) expenses reimbursable under Section 3.2 above incurred on or prior to the Termination Date but not yet reimbursed;
and 
 (iv) any amounts or benefits that are vested amounts or vested benefits or that the Executive is otherwise entitled to
receive under any Company plan, program, policy or practice (with the exception of those, if any, relating to severance) on the Termination Date, in accordance with such plan, program, policy, or practice. 

Section 4.3. Termination Resulting from Death or Disability. 

(a) As the result of any Disability suffered by the Executive, the Company may, upon five (5) days prior notice to the Executive,
terminate the Executive’s employment under this Agreement. The Executive’s employment shall automatically terminate upon his death. 

(b) “Disability” means a determination by the Company in accordance with applicable law that as a result of a physical or
mental injury or illness, the Executive is unable to perform the essential functions of his job with or without reasonable accommodation for a period of (i) ninety (90) consecutive days; or (ii) one hundred twenty (120) days during
any twelve (12) month period. 
 (c) If the Executive’s employment is terminated pursuant to Section 4.3(a), the
Executive or the Executive’s estate, as the case may be, shall be entitled to receive, and the Company’s sole obligation under this Agreement or otherwise shall be to pay or provide to the Executive or the Executive’s estate, as the
case may be, the Accrued Obligations. 
 Section 4.4. Release Agreement. In order to receive the Severance Payments or the COBRA
Assistance set forth in Section 4.1 (if eligible), the Executive must timely execute (and not revoke) a separation agreement and general release (the “Release Agreement”) in a customary form as is determined to be reasonably
necessary by the Company in its good faith and reasonable discretion. If the Executive is eligible for Severance Payments and COBRA Assistance pursuant to Section 4.1, the Company will deliver the Release Agreement to the Executive
within seven (7) calendar days following the Termination Date. The Severance Payments and COBRA Assistance are subject to the Executive’s execution of such Release Agreement within 45 days of the Executive’s receipt of the Release
Agreement and the Executive’s non-revocation of such Release Agreement. 

  
 -7- 

 Section 4.5. Post-Termination Breach. Notwithstanding anything to the contrary
contained in this Agreement, the Company’s obligations to provide the Severance Payments and the COBRA Assistance will immediately cease if the Executive breaches any of the provisions of the Covenants Agreement, the Release Agreement or any
other agreement the Executive has with the Company. 
 Section 4.6. Removal from any Boards and Position. If the
Executive’s employment is terminated for any reason under this Agreement, he shall be deemed (without further action, deed or notice) to resign (i) if a member, from the Board or board of directors (or similar governing body) of any
Affiliate of the Company or any other board to which he has been appointed or nominated by or on behalf of the Company and (ii) from all other positions with the Company or any subsidiary or other Affiliate of the Company, including, but not
limited to, as an officer of the Company and any of its subsidiaries or other Affiliates. 
 ARTICLE 5 

GENERAL PROVISIONS 

Section 5.1. Company Non-Disclosure and Invention Assignment Agreement. The Executive
acknowledges and confirms that the Non-Disclosure and Invention Assignment Agreement executed by the Executive in favor of the Company on April 8, 2016 (“Covenants Agreement”), the terms
of which are incorporated herein by reference, remains in full force and effect and binding upon the Executive. The Covenants Agreement shall survive the termination of this Agreement and the Executive’s employment by the Company for the
applicable period(s) set forth therein.     
 Section 5.2. Expenses. Each of the Company and the Executive
shall bear its/his own costs, fees and expenses in connection with the negotiation, preparation and execution of this Agreement. 

Section 5.3. Entire Agreement. This Agreement and the Covenants Agreement contain the entire agreement of the parties hereto with
respect to the terms and conditions of the Executive’s employment during the Term and activities following termination of this Agreement and the Executive’s employment with the Company and supersede any and all prior agreements and
understandings, whether written or oral, between the parties hereto with respect to the subject matter of this Agreement or the Covenants Agreement. Each party hereto acknowledges that no representations, inducements, promises or agreements, whether
oral or in writing, have been made by any party, or on behalf of any party, which are not embodied herein or in the Covenants Agreement. The Executive acknowledges and agrees that the Company has fully satisfied, and has no further, obligations to
the Executive arising under, or relating to, any other employment or consulting arrangement or understanding (including, without limitation, any claims for compensation or benefits of any kind) or otherwise. No agreement, promise or statement not
contained in this Agreement or the Covenants Agreement shall be valid and binding, unless agreed to in writing and signed by the parties sought to be bound thereby. 

  
 -8- 

 Section 5.4. No Other Contracts. The Executive represents and warrants to the
Company that neither the execution and delivery of this Agreement by the Executive nor the performance by the Executive of the Executive’s obligations hereunder, shall constitute a default under or a breach of the terms of any other agreement,
contract or other arrangement, whether written or oral, to which the Executive is a party or by which the Executive is bound, nor shall the execution and delivery of this Agreement by the Executive nor the performance by the Executive of his duties
and obligations hereunder give rise to any claim or charge against either the Executive, the Company or any Affiliate, based upon any other contract or other arrangement, whether written or oral, to which the Executive is a party or by which the
Executive is bound. The Executive further represents and warrants to the Company that he is not a party to or subject to any restrictive covenants, legal restrictions or other agreement, contract or arrangement, whether written or oral, in favor of
any entity or person which would in any way preclude, inhibit, impair or limit the Executive’s ability to perform his obligations under this Agreement or the Covenants Agreement, including, but not limited to,
non-competition agreements, non-solicitation agreements or confidentiality agreements. The Executive shall defend, indemnify and hold the Company harmless from and
against all claims, actions, losses, liabilities, damages, costs and expenses (including reasonable attorney’s fees and amounts paid in settlement in good faith) arising from or relating to any breach of the representations and warranties made
by the Executive in this Section 5.4. 
 Section 5.5. Notices. Any notice or other communication required or
permitted hereunder shall be in writing and shall be delivered personally or sent by nationally recognized overnight courier service (with next business day delivery requested). Any such notice or communication shall be deemed given and effective,
in the case of personal delivery, upon receipt by the other party, and in the case of a courier service, upon the next business day, after dispatch of the notice or communication. Any such notice or communication shall be addressed as follows: 

 

	
	 If to the Company, to:

	
	 Adgero Biopharmaceuticals Holdings, Inc.

	 3 Davenport Drive

	 Princeton Junction, NJ 08555

	 Attn: Chief Executive Officer

	
	 With a copy to:

	
	 Lowenstein Sandler LLP

	 1251 Avenue of the Americas

	 New York, New York 10020

	 Attn: Michael J. Lerner, Esq.

	
	 If to the Executive, to:

	
	 Steven J. Rychnovsky

	
	
                      
                      

	
                      
                      

	
	 With a copy to:

	
	
                      
                      

	
                      
                      

  
 -9- 

 Any person named above may designate another address or fax number by giving notice in accordance with this
Section to the other persons named above. 
 Section 5.6. Governing Law; Jurisdiction. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of New Jersey, without regard to principles of conflicts of law. Any and all actions arising out of this Agreement or Employee’s employment by Company or termination therefrom shall be brought
and heard in the state and federal courts of the State of New Jersey and the parties hereto hereby irrevocably submit to the exclusive jurisdiction of any such courts. THE COMPANY AND THE EXECUTIVE HEREBY WAIVE THEIR RESPECTIVE RIGHT TO TRIAL BY
JURY IN ANY ACTION CONCERNING THIS AGREEMENT OR ANY AND ALL MATTERS ARISING DIRECTLY OR INDIRECTLY HEREFROM AND REPRESENT THAT THEY HAVE CONSULTED WITH COUNSEL OF THEIR CHOICE OR HAVE CHOSEN VOLUNTARILY NOT TO DO SO SPECIFICALLY WITH RESPECT TO THIS
WAIVER.     
 Section 5.7. Waiver. Either party hereto may waive compliance by the other party with any
provision of this Agreement. The failure of a party to insist on strict adherence to any term of this Agreement on any occasion shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that
term or any other term of this Agreement. No waiver of any provision shall be construed as a waiver of any other provision. Any waiver must be in writing. 

Section 5.8. Severability. If any one or more of the terms, provisions, covenants and restrictions of this Agreement shall be
determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected,
impaired or invalidated and the parties will attempt to agree upon a valid and enforceable provision which shall be a reasonable substitute for such invalid and unenforceable provision in light of the tenor of this Agreement, and, upon so agreeing,
shall incorporate such substitute provision in this Agreement. In addition, if any one or more of the provisions contained in this Agreement shall for any reason be determined by a court of competent jurisdiction to be excessively broad as to
duration, geographical scope, activity or subject, it shall be construed, by limiting or reducing it, so as to be enforceable to the extent compatible with then applicable law. 

Section 5.9. Counterparts. This Agreement may be executed in any number of counterparts and each such duplicate counterpart shall
constitute an original, any one of which may be introduced in evidence or used for any other purpose without the production of its duplicate counterpart. Moreover, notwithstanding that any of the parties did not execute the same counterpart, each
counterpart shall be deemed for all purposes to be an original, and all such counterparts shall constitute one and the same instrument, binding on all of the parties hereto. 

  
 -10- 

 Section 5.10. Advice of Counsel. This Agreement was prepared by Lowenstein
Sandler LLP in its capacity as legal counsel to the Company. Both parties hereto acknowledge that they have had the opportunity to seek and obtain the advice of counsel before entering into this Agreement and have done so to the extent desired, and
have fully read the Agreement and understand the meaning and import of all the terms hereof. 
 Section 5.11. Assignment. This
Agreement shall inure to the benefit of the Company and its successors and assigns (including, without limitation, the purchaser of all or substantially all of its assets) and shall be binding upon the Company and its successors and assigns. This
Agreement is personal to the Executive, and the Executive shall not assign or delegate his rights or duties under this Agreement, and any such assignment or delegation shall be null and void. 

Section 5.12. Agreement to Take Actions. Each party to this Agreement shall execute and deliver such documents, certificates,
agreements and other instruments, and shall take all other actions, as may be reasonably necessary or desirable in order to perform his or its obligations under this Agreement. 

Section 5.13. No Attachment. Except as required by law, no right to receive payments under this Agreement shall be subject to
anticipation, commutation, alienation, sale, assignment, encumbrance, charge, pledge, or hypothecation or to execution, attachment, levy or similar process or assignment by operation of law, and any attempt, voluntary or involuntary, to effect any
such action shall be null, void and of no effect; provided, however, that nothing in this Section 5.13 shall preclude the assumption of such rights by executors, administrators or other legal representatives of the
Executive or the Executive’s estate and their assigning any rights hereunder to the person or persons entitled thereto. 

Section 5.14. Source of Payment. Except as otherwise provided under the terms of any applicable employee benefit plan, all
payments provided for under this Agreement shall be paid in cash from the general funds of Company. The Company shall not be required to establish a special or separate fund or other segregation of assets to assure such payments, and, if the Company
shall make any investments to aid it in meeting its obligations hereunder, the Executive shall have no right, title or interest whatever in or to any such investments except as may otherwise be expressly provided in a separate written instrument
relating to such investments. Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind, or a fiduciary relationship, between the Company and the Executive or any
other person. To the extent that any person acquires a right to receive payments from the Company hereunder, such right, without prejudice to rights which employees may have, shall be no greater than the right of an unsecured creditor of the
Company. The Executive shall not look to the owners of the Company for the satisfaction of any obligations of the Company under this Agreement. 

  
 -11- 

 Section 5.15. Tax Withholding. The Company or other payor is authorized to
withhold from any benefit provided or payment due hereunder, the amount of withholding taxes due any federal, state or local authority in respect of such benefit or payment and to take such other action as may be necessary in the opinion of the
Board to satisfy all obligations for the payment of such withholding taxes. The Executive will be solely responsible for all taxes assessed against him with respect to the compensation and benefits described in this Agreement, other than typical
employer-paid taxes such as FICA, and the Company makes no representations as to the tax treatment of such compensation and benefits. 

Section 5.16. 409A Compliance. All payments under this Agreement are intended to comply with or be exempt from the requirements of
Section 409A of the Code and regulations promulgated thereunder (“Section 409A”). As used in this Agreement, the “Code” means the Internal Revenue Code of 1986, as amended. To the extent permitted under
applicable regulations and/or other guidance of general applicability issued pursuant to Section 409A, the Company reserves the right to modify this Agreement to conform with any or all relevant provisions regarding compensation and/or benefits
so that such compensation and benefits are exempt from the provisions of 409A and/or otherwise comply with such provisions so as to avoid the tax consequences set forth in Section 409A and to assure that no payment or benefit shall be subject
to an “additional tax” under Section 409A. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section 409A, or to the extent any provision in this Agreement must be modified to comply with
Section 409A, such provision shall be read in such a manner so that no payment due to the Executive shall be subject to an “additional tax” within the meaning of Section 409A(a)(1)(B) of the Code. If necessary to comply with the
restriction in Section 409A(a)(2)(B) of the Code concerning payments to “specified employees,” any payment on account of the Executive’s separation from service that would otherwise be due hereunder within six (6) months
after such separation shall be delayed until the first business day of the seventh month following the Termination Date and the first such payment shall include the cumulative amount of any payments (without interest) that would have been paid prior
to such date if not for such restriction. Each payment in a series of payments hereunder shall be deemed to be a separate payment for purposes of Section 409A. In no event may the Executive, directly or indirectly, designate the calendar year
of payment. All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred
during the Executive’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other
calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (iv) the right to reimbursement is not subject to
liquidation or exchange for another benefit. Notwithstanding anything contained herein to the contrary, the Executive shall not be considered to have terminated employment with the Company for purposes of Section 4.1 unless the Executive
would be considered to have incurred a “termination of employment” from the Company within the meaning of Treasury Regulation §1.409A-1(h)(1)(ii). In no event whatsoever shall the Company be
liable for any additional tax, interest or penalty that may be imposed on the Executive by Section 409A or damages for failing to comply with Section 409A. 

  
 -12- 

 Section 5.17. 280G Modified Cutback. 

(a) If any payment, benefit or distribution of any type to or for the benefit of the Executive, whether paid or payable, provided or to be
provided, or distributed or distributable pursuant to the terms of this Agreement or otherwise (collectively, the “Parachute Payments”) would subject the Executive to the excise tax imposed under Section 4999 of the Code (the
“Excise Tax”), the Parachute Payments shall be reduced so that the maximum amount of the Parachute Payments (after reduction) shall be one dollar ($1.00) less than the amount which would cause the Parachute Payments to be subject to
the Excise Tax; provided that the Parachute Payments shall only be reduced to the extent the after-tax value of amounts received by the Executive after application of the above reduction would exceed the after-tax value of the amounts received without application of such reduction. For this purpose, the after-tax value of an amount shall be determined taking into account all
federal, state, and local income, employment and excise taxes applicable to such amount. Unless the Executive shall have given prior written notice to the Company to effectuate a reduction in the Parachute Payments if such a reduction is required,
which notice shall be consistent with the requirements of Section 409A to avoid the imputation of any tax, penalty or interest thereunder, then the Company shall reduce or eliminate the Parachute Payments by first reducing or eliminating any
cash payments (with the payments to be made furthest in the future being reduced first), then by reducing or eliminating accelerated vesting of stock options or similar awards, and then by reducing or eliminating any other remaining Parachute
Payments; provided, that no such reduction or elimination shall apply to any non-qualified deferred compensation amounts (within the meaning of Section 409A) to the extent such reduction or elimination
would accelerate or defer the timing of such payment in manner that does not comply with Section 409A. 
 (b) An initial determination
as to whether (x) any of the Parachute Payments received by the Executive in connection with the occurrence of a change in the ownership or control of the Company or in the ownership of a substantial portion of the assets of the Company shall
be subject to the Excise Tax, and (y) the amount of any reduction, if any, that may be required pursuant to the previous paragraph, shall be made by an independent accounting firm selected by the Company (the “Accounting Firm”)
prior to the consummation of such change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company. The Executive shall be furnished with notice of all determinations made as to
the Excise Tax payable with respect to the Executive’s Parachute Payments, together with the related calculations of the Accounting Firm, promptly after such determinations and calculations have been received by the Company. 

(c) For purposes of this Section 5.17, (i) no portion of the Parachute Payments the receipt or enjoyment of which the Executive
shall have effectively waived in writing prior to the date of payment of the Parachute Payments shall be taken into account; (ii) no portion of the Parachute Payments shall be taken into account which in the opinion of the Accounting Firm does
not constitute a “parachute payment” within the meaning of Section 280G(b)(2) of the Code; (iii) the Parachute Payments shall be reduced only to the extent necessary so that the Parachute Payments (other than those referred to in
the immediately preceding clause (i) or (ii)) in their entirety constitute reasonable compensation for services actually rendered within the meaning of Section 280G(b)(4) of the Code or are otherwise not subject to disallowance as
deductions, in the opinion of the auditor or tax counsel referred to in such clause (ii); and (iv) the value of any non-cash benefit or any deferred payment or benefit included in the Parachute Payments
shall be determined by the Company’s independent auditors based on Sections 280G and 4999 of the Code and the regulations for applying those sections of the Code, or on substantial authority within the meaning of Section 6662 of the Code.

  
 -13- 

 Section 5.18. Recoupment of Erroneously Awarded Compensation. Any
incentive-based or other compensation paid to the Executive under this Agreement or any other agreement or arrangement with the Company which is subject to recovery under any law, government regulation, stock exchange listing requirement or any
clawback policy adopted by the Company from time to time will be subject to the deductions and clawback as may be required by such law, government regulation, stock exchange listing requirement or clawback policy.    In addition,
if the executive is or becomes an executive officer subject to the incentive compensation repayment requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), then if required by the
Dodd-Frank Act or any of its regulations he will enter into an amendment to this Agreement or a separate written agreement with the Company to comply with the Dodd-Frank Act and any of its regulations. 

Section 5.19. Certain Definitions. As used in this Agreement, “Change in Control” means (x) a change in
ownership of the Company under clause (i) below or (y) a change in the ownership of a substantial portion of the assets of the Company under clause (ii) below: 

(i) Change in the Ownership of the Company. A change in the ownership of the Company shall occur on the date that any
one person, or more than one person acting as a group (as defined in clause (iii) below), acquires ownership of capital stock of the Company that, together with capital stock held by such person or group, constitutes more than 50 percent
of the total fair market value or total voting power of the capital stock of the Company. However, if any one person or more than one person acting as a group, is considered to own more than 50 percent of the total fair market value or total
voting power of the capital stock of the Company, the acquisition of additional capital stock by the same person or persons shall not be considered to be a change in the ownership of the Company. An increase in the percentage of capital stock owned
by any one person, or persons acting as a group, as a result of a transaction in which the Company acquires capital stock in the Company in exchange for property will be treated as an acquisition of stock for purposes of this
paragraph.     
 (ii) Change in the Ownership of a Substantial Portion of the Company’s
Assets. A change in the ownership of a substantial portion of the Company’s assets shall occur on the date that any one person, or more than one person acting as a group (as defined in clause (iii) below), acquires (or has acquired
during the 12-month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than 80 percent
of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions. For this purpose, gross fair market value means the value of the assets of the Company, or the value of the assets being
disposed of, determined without regard to any liabilities associated with such assets. There is no Change in Control under this clause (ii) when there is a transfer to an entity that is controlled by the shareholders of the Company immediately
after the transfer, as provided below in this clause (ii). A transfer of assets by the Company is not treated as a change in the ownership of such assets if the assets are transferred to (a) a shareholder of the Company (immediately before the
asset transfer) in exchange for or with respect to its capital stock, (b) an entity, 50 percent or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (c) a person, or more than one
person acting as a 

  
 -14- 

 
group, that owns, directly or indirectly, 50 percent or more of the total value or voting power of all the outstanding capital stock of the Company, or (d) an entity, at least
50 percent of the total value or voting power of which is owned, directly or indirectly, by a person described in clause (ii)(c) of this paragraph. For purposes of this clause (ii), a person’s status is determined immediately after the
transfer of the assets. 
 (iii) Persons Acting as a Group. For purposes of clauses (i) and (ii) above, persons
will not be considered to be acting as a group solely because they purchase or own capital stock or purchase assets of the Company at the same time. However, persons will be considered to be acting as a group if they are owners of a corporation that
enters into a merger, consolidation, purchase or acquisition of assets or capital stock, or similar business transaction with the Company. If a person, including an entity, owns stock in both corporations that enter into a merger, consolidation,
purchase or acquisition of assets or capital stock, or similar transaction, such shareholder is considered to be acting as a group with other shareholders in a corporation only with respect to the ownership in that corporation before the transaction
giving rise to the change and not with respect to the ownership interest in the other corporation. For purposes of this paragraph, the term “corporation” shall have the meaning assigned such term under Treasury Regulation section 1.280G-1, Q&A-45. 
 (iv) Each of
clauses (i) through (iii) above shall be construed and interpreted consistent with the requirements of Section 409A and any Treasury Regulations or other guidance issued thereunder. 

[Signature Page Follows] 

  
 -15- 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and
year first above written. 
  

			
	COMPANY
	
	ADGERO BIOPHARMACEUTICALS
	HOLDINGS, INC.
		
	By:	 	 /s/ Frank Pilkiewicz

	Name: Frank Pilkiewicz
	Title: President
	
	EXECUTIVE
	
	 /s/ Steven J. Rychnovsky

Steven J. Rychnovsky

 [SIGNATURE PAGE TO EMPLOYMENT
AGREEMENT]EX-10.37

 Exhibit 10.37 

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, INCENTIVE STOCK OPTION GRANT AGREEMENT 

AND NONQUALIFIED STOCK OPTION GRANT AGREEMENT 

This Amendment No. 1 (the “Amendment”) to that certain Employment Agreement (the “Employment
Agreement”) by and between Steve Rychnovsky (the “Employee”) and Adgero Biopharmaceuticals Holdings, Inc. (the “Company”) and to that certain Incentive Stock Option Grant Agreement (the
“ISO Agreement”) by and between the Employee and the Company and to that certain Nonqualified Stock Option Grant Agreement (the “NQSO Agreement”) by and between the Employee and the Company, is
effective as of February 8, 2017. 
 WHEREAS, the Employment Agreement sets forth the terms and conditions of Employee’s
employment with the Company; 
 WHEREAS, the Company and Employee desire to amend the Employment Agreement to provide for full
acceleration of unvested options upon certain change in control terminations; 
 WHEREAS, the Company and Employee desire to amend
the vesting schedule in the ISO Agreement and the NQSO Agreement to provide for full acceleration of unvested options upon certain change in control terminations; 

WHEREAS, Section 5.3 of the Employment Agreement provides that the Employment Agreement may be amended pursuant to an instrument
in writing between the Company and Employee; and 
 WHEREAS, Section 12 of the ISO Agreement and the NQSO Agreement provides
that the ISO Agreement and the NQSO Agreement may be amended pursuant to an instrument in writing between the Company and Employee. 

NOW, THEREFORE, the Company and Employee hereby agree that the Employment Agreement, the ISO Agreement and the NQSO Agreement shall be
amended as follows: 
  

	 	1.	 The third sentence of Section 3.1(c) of the Employment Agreement is hereby amended and restated to read as
follows: 

 “Notwithstanding anything in the Plan to the contrary, if the Executive is terminated without Cause (as
defined in Section 4.1(b)) or resigns with Good Reason (as defined in Section 4.1(c)) within twenty-four (24) months following a Change in Control (as defined in Section 5.19), in lieu of the application of
Section 4.1(d)(ii), the Executive shall receive accelerated vesting of all unvested options upon the Termination Date and all of the Executive’s outstanding vested stock options shall remain exercisable for a period of nine
(9) months, measured from the Termination Date (but in no event later than the expiration date of their term); provided, however, that in the event stock options under the Plan are cancelled or otherwise terminated pursuant to the Plan in
connection with such Change in Control, the Executive’s stock options may be cancelled or otherwise terminated, as applicable, on terms no less favorable than those provided to other similarly situated option holders.” 

 

	 	2.	 Section (f) of Exhibit A of the ISO Agreement and the NQSO Agreement is hereby amended and restated as
follows: 

 “Vesting Schedule: The shares subject to the option shall vest in three (3) equal annual
installments, beginning on the first anniversary of the date of grant, and continuing on each of the second and third anniversaries, provided that the Optionee remains a service provider to the Company through each applicable vesting date.
Notwithstanding the foregoing, pursuant to the terms of the Employment Agreement by and between the Company and the Optionee dated April 8, 2016 (the “Employment Agreement”), (i) if the Company experiences a Change in Control
(as defined in the Employment Agreement) and within twenty-four (24) months following the Change in Control, the Company terminates the Optionee’s employment without Cause (as defined in the Employment Agreement) or the Optionee resigns
for Good Reason (as defined in the Employment Agreement), then upon such termination all unvested options shall vest upon the Termination Date (as defined in the Employment Agreement) or (ii) if (other than within twenty-four (24) months
following a Change in Control) the Company terminates the Optionee’s employment without Cause (as defined in the Employment Agreement) or the Optionee resigns for Good Reason (as defined in the Employment Agreement), then upon such termination
a number of options shall automatically vest equal to the number of unvested options that would have vested had the Optionee remained continuously employed by the Company during the period beginning on the date of such termination and ending on the
six (6) month anniversary of the date of such termination (i.e., options representing fifty (50%) percent (6 months out of 12) of the options that would have vested on the next annual vesting date will vest on the Termination Date (as
defined in the Employment Agreement)).” 

	 	3.	 This Amendment shall supersede all prior agreements, whether oral or written, between the parties with respect
to the subject matter herein. 

  

	 	4.	 Except as amended herein, the Employment Agreement, the ISO Agreement and the NQSO Agreement shall remain in
full force and effect. 

  

	 	5.	 This Amendment may be executed in several counterparts, each of which is deemed to be an original but all of
which together will constitute one and the same instrument. This Amendment may be delivered via facsimile or scanned “PDF” which shall be an original for all purposes. 

[Signature Page Follows] 

  
 -2- 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment as of this 8th day of February, 2017. 
  

	
	Adgero Biopharmaceuticals Holdings, Inc.
	
	 /s/ Frank G. Pilkiewicz

	Name: Frank G. Pilkiewicz
	Title: Presidet and CEO
	
	Employee
	
	 /s/ Steve Rychnovsky

	Steve Rychnovsky

  
 -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]